Cardiovascular Systems — Investor Day (July 2018)
59 slides from Cardiovascular Systems's investor day presentation, Jul 31, 2018
Slide 1: Analyst Day Meeting
Analyst Day Meeting Scott R. Ward Chairman, President & CEO July 31, 2018
Slide 2: Safe Harbor
Safe Harbor FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Report Act of 1995, which are provided under the protection of the safe harbor for forward-looking statements provided by that Act. For example, statem
Slide 3: Agenda
Agenda Overview: Scott Ward Clinician’s Perspective: Dr. Martin Leon Driving Sustainable Long-Term Growth: Rhonda Robb Clinician’s Perspective: Dr. David Kandzari Growth Summary & Financial Performance: Jeff Points Closing Comments: Scott Ward Physician Q&A: Dr. Martin Leon and Dr. David Kandzari CS
Slide 4: Cardiovascular Systems, Inc. Overview
Cardiovascular Systems, Inc. Overview Historical Revenue Highly Differentiated and Proprietary Core Technology $300 10% 3-Year CAGR Serving Large and Growing Markets $250 $217 $205 $200 $178 Complex and Difficult Disease State $150 Robust Medical Evidence (Millions) $100 Large and Established U.S. S
Slide 5: Commitment to Our Mission
Commitment to Our Mission Saving Limbs, Saving Lives Every Day Focused on Complex Peripheral and Coronary Artery Disease 2 Million+ 160,000 370,000 525,000 Deaths Annually From High Risk or Complex Patients with Critical Annual Amputations Coronary Artery High Risk Procedures Limb Ischemia (CLI)1 in
Slide 6: Experienced and Talented Team
Experienced and Talented Team Average Experience in Medical Technology: 18 Years Scott R. Ward, MS, MBA Jeffrey S. Points, MBA, Rhonda J. Robb, MBA Chairman, CPA Chief Operating Officer President and CEO Chief Financial Officer Alexander Rosenstein, Ryan D. Egeland, MD David S. Whitescarver, JD PhD
Slide 7: CSI Today
CSI Today # 1 67 K >700 80 Market leadership 227 Patients treated of Mission Driven Engineers in calcified peripheral & Patents annually Employees and Scientists coronary atherectomy FY18 8% 68% Other Peripheral OAS $217M In Revenue 1% 23% International Coronary OAS
Slide 8: Strong Financial Platform for Growth
Strong Financial Platform for Growth Profitable Business Model: FY18 Net Income $1.7M Revenues Gross Margin Adjusted EBITDA Cash Balance 10% +80% +$56M +$56M CAGR $16.5M $217M $12.9M $205M 82% $116.3M $107.9M $178M 81% FY16 FY17 FY18 $60.6M 80% $(39.2)M FY16 FY17 FY18 FY16 FY17 FY18 FY16 FY17 FY18
Slide 9: Driving Sustainable Growth: Broaden Our Value Streams
Driving Sustainable Growth: Broaden Our Value Streams • Financial Goal: Five Year CAGR of 15 - 18% and Revenue of $435M - $500M in FY23 Financial Strength and the Talent to Execute Grow and Protect the Core Business Growth, Profitability, Cash and Liquidity Sustain Market Leadership Experienced and
Slide 10: Appendix: Non-GAAP Financial Measures
Appendix: Non-GAAP Financial Measures To supplement CSI's consolidated condensed financial statements prepared in accordance with GAAP, CSI uses a non-GAAP financial measure referred to as "Adjusted EBITDA" in this presentation. Reconciliations of this non-GAAP measure to the most comparable U.S. GA
Slide 11: Appendix: Non-GAAP Financial Measures
Appendix: Non-GAAP Financial Measures The following is an explanation of each of the items that management excluded from Adjusted EBITDA and the reasons for excluding each of these individual items: -- Stock-based compensation. CSI excludes stock-based compensation expense from its non-GAAP financia
Slide 12: Driving Sustainable, Long-Term Growth
Driving Sustainable, Long-Term Growth Rhonda Robb Chief Operating Officer July 31, 2018
Slide 13: Safe Harbor
Safe Harbor FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Report Act of 1995, which are provided under the protection of the safe harbor for forward-looking statements provided by that Act. For example, statem
Slide 14: Key Growth Drivers
Key Growth Drivers Core Business New Geographies Innovation Achieve $435M - $500M in Revenue in FY23 (15% - 18% CAGR)
Slide 15: CSI Will Remain Focused on Complex Coronary and Peripheral Disease
CSI Will Remain Focused Complex Coronary and Peripheral Disease Large, and growing markets with significant unmet medical needs Aging Patient Populations CSI market leadership with OAS in peripheral and coronary segments Opportunities for Innovation Focused on Complex Peripheral and Coronary Artery
Slide 16: Key Growth Drivers: Core Business
Key Growth Drivers Innovation in product line extensions Site of service strategies Evidence Core Business Expertise Excellence in quality and manufacturing Sustain 10+ % Growth in our Core Business
Slide 17: Innovation: Ease of Use with OAS Enhancements
Innovation Ease of Use with OAS Enhancements GlideAssist is an innovative solution that: • Facilitates device tracking • Provides easier device repositioning • Exceptional performance especially in challenging anatomies ViperWire Flex Tip and Next Generation Pump launching in FY19 Video with represe
Slide 18: Innovation: Radial is a Core Competitive Advantage
Innovation Radial is a Core Competitive Advantage A new differentiated route of access for CSI, complementary to tibial/pedal Diamondback low 5Fr profile, with extended working length enables unique radial approach Expansion in portfolio of radial support devices: wires, sheaths, catheters, PTA ball
Slide 19: Innovation: Complete Revascularization Differentiators
Innovation Complete Revascularization Differentiators Maximize Sales Productivity Broader portfolio to treat more patients with Interventional Support Products with small and larger vessels Sapphire balloons, 1.0mm specialty balloons New 1.0mm solution for sub- and chronic total occlusions Microcath
Slide 20: Innovation: Peripheral Exchangeable Platform
Innovation Complete Revascularization Differentiators Peripheral Exchangeable Platform Up to 50% of peripheral patients have multi-level disease Innovation facilitates utilization of multiple crowns during a single case Patient and economic benefits Business model innovation may enable new product c
Slide 21: Site of Service Strategies
Site of Service Strategies Customer Focused and Targeted to Drive Share/Volume Peripheral Peripheral Coronary Hospital Office Based Lab Dedicated coronary reps and Adaptive sales model given support needs, clinical specialists clinical specialists Educational excellence Long-term contracts with pric
Slide 22: Leadership in Clinical Evidence
Leadership in Clinical Evidence 5000+ 7000 600 Patients Lesions Physicians Trial Size Importance • “All-comers” trial vs. any other treatment LIBERTY 360° (Enrollment Complete) n=1,204 • Nearly 700 Rutherford Class 4-6 patients enrolled • OAS + DCB vs. DCB alone PAD OPTIMIZE (Enrollment Complete) n=
Slide 23: Leadership in Medical Evidence: ECLIPSE
Leadership in Medical Evidence ECLIPSE Will Drive OAS as Standard of Care for Vessel Preparation Trial designed to establish a new standard of care of vessel preparation for patients with complex coronary disease Enrolling 2000 patients, 100 sites 400+ enrollments to date Enrollment completion expec
Slide 24: Medical Evidence: Peripheral Evidence Driving Guidelines
Medical Evidence Peripheral Evidence Driving Guidelines 2016 AHA/ACC Guidelines on the 2 Year Clinical Data Presented; Management of Patients with PAD1 AMP August 8, 2018 Economic Data Presented FY19 Initiating 500 patient BTK An evaluation for revascularization study in 2019 options should be perfo
Slide 25: Excellence in Quality and Manufacturing
Excellence in Quality and Manufacturing Scalable and Continuous COGS Reductions Manufacturing Volume driven overhead leverage Initiatives Labor productivity Scalable and continuous reductions LEAN continuous improvement protect margins from likely ASP declines Material cost reductions Sourcing and o
Slide 26: Key Growth Drivers: New Geographies
Key Growth Drivers Japan Launch Expanding Steady Cadence New Geographies Progressing Well Global Distribution of New Product Network Introductions New Geographies to Provide $25M-$50M in Revenue in FY23
Slide 27: Japan Launch Progressing Well
Japan Launch Progressing Well Japan launch is progressing on plan Calcific burden in Japan significant Physicians accept need/value of vessel preparation Medikit is the exclusive distribution partner in Japan Coronary Classic and ViperWire Flex launch early 2019 Initiate enrollment of Peripheral OAS
Slide 28: Expand Global Distribution Network
Expand Global Distribution Network
Slide 29: Expand Global Distribution Network
Expand Global Distribution Network Global interventional solutions provider Leadership team and distribution strength Footprint in more than 60 countries and Immediate CSI access to key markets across six continents Strong customer relationships; reputation Focus and ability to leverage infrastructu
Slide 30: A Steady Cadence of New Geographies
A Steady Cadence of New Geographies FY19 FY23 $25M-$50M in FY23 FY19 FY23 Japan $25M - $50M Europe Middle East Southeast Asia $15M - $17.5M Canada $1.8M China FY18 FY21 FY23 Coronary Peripheral
Slide 31: Key Growth Drivers: Innovation
Key Growth Drivers Innovation drives long term growth potential 20 new product launches by FY23 Portfolio expansion into complex Innovation coronary and peripheral patients $70M-$100M in Revenue From New Products in FY23
Slide 32: Building a Cardiovascular Company: Steady Cadence of Product Launches
Building a Cardiovascular Company Steady Cadence of 20 Product Launches Through FY23 Innovation Will Drive $70M-$100M in Revenue in Fiscal 2023 Platforms Peripheral Products Coronary Products Support Products ViperWire Flex Laser Mixed Plaque Atherectomy Atherectomy OAS Gen III Scoring Balloons cPCI
Slide 33: Unmet Needs Shape our Innovation Strategy: Complex Coronary Patient
Unmet Needs Shape our Innovation Strategy Complex Coronary Patient 16-18 Million Coronary Artery Disease1 ~1.2 Million Annual CAD Interventions (PCI or CABG)2 880k PCI3 525k Complex4 ~150k-200k Core OAS cPCI* PCI Support CTO/STO In Stent High Risk Innovations – Hemodynamic 4 Products Products Resten
Slide 34: CSI cPCI Hemodynamic Support
CSI cPCI Hemodynamic Support Video with representation of proposed product
Slide 35: Unmet Needs Shape Our Innovation: Complex Peripheral Patient
Unmet Needs Shape Our Innovation Complex Peripheral Patient 20 Million Peripheral Arterial Disease1 ~5.7 Million CSI Strategic Approach Diagnosed Critical Limb Ischemia or Intermittent Claudicant 2 CSI will provide a full product line to serve patients with varying degrees of 900k PAD burden Annual
Slide 36: Future Innovation: Vessel Preparation for Mixed Plaque
Future Innovation Vessel Preparation for Mixed Plaque CSI and Aerolase Corp. Development Agreement Laser Atherectomy Catheter Treats Soft Plaque and ISR
Slide 37: Future Innovation: Vessel Preparation for Soft Plaque/ISR
Future Innovation Vessel Preparation for Soft Plaque/ISR Large and attractive market, complimentary to OAS; expands the patient population that CSI will serve in a segment lacking innovation Target patients: De novo soft plaque and ISR in the peripheral patients; expand to Coronary Leverage existing
Slide 38: Driving Sustainable Long-Term Growth: Key Value Drivers and Milestones
Driving Sustainable Long-Term Growth Key Value Drivers Key Milestones Future Revenue 2019-2020 5 - Year CAGR 15% – 18% $435M - $500M • ViperWire, Next Gen Pump• PCI Support Portfolio • Radial Support Portfolio • Japan, Europe, Middle East, Asia • Peripheral Exchangeable $300M - $350M 2021-2022 $240M
Slide 39: Driving Sustainable Growth: Broaden Our Value Streams
Driving Sustainable Growth: Broaden Our Value Streams Financial Goal: Five Year CAGR of 15% - 18% & Revenue of $435M - $500M in FY23 Financial Strength and the Talent to Execute Grow and Protect the Core Business Growth, Profitability, Cash and Liquidity Sustain Market Leadership Experienced and Tal
Slide 40: Appendix: Non-GAAP Financial Measures
Appendix: Non-GAAP Financial Measures To supplement CSI's consolidated condensed financial statements prepared in accordance with GAAP, CSI uses a non-GAAP financial measure referred to as "Adjusted EBITDA" in this presentation. Reconciliations of this non-GAAP measure to the most comparable U.S. GA
Slide 41: Appendix: Non-GAAP Financial Measures
Appendix: Non-GAAP Financial Measures The following is an explanation of each of the items that management excluded from Adjusted EBITDA and the reasons for excluding each of these individual items: -- Stock-based compensation. CSI excludes stock-based compensation expense from its non-GAAP financia
Slide 42: Growth Summary and Financial Performance
Growth Summary and Financial Performance Jeff Points Chief Financial Officer July 31, 2018
Slide 43: Safe Harbor
Safe Harbor FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Report Act of 1995, which are provided under the protection of the safe harbor for forward-looking statements provided by that Act. For example, statem
Slide 44: Strong and Stable Business Model
Strong and Stable Business Model Cash and Liquidity $116M in cash and cash equivalents Recurring cash flow $40M line of credit at June 30, 2018 generated from operations unused and available Revenue Adjusted EBITDA Gross Margin (Millions) (Millions) CAGR = 12% $217 $16 82% $205 $13 81% $182 $178 80%
Slide 45: Platform for Growth
Platform for Growth Growth through geographic expansion and innovation Organic growth investments are internally funded ~$250M R&D investments increase to 14%-17% FY19-FY23 R&D Investments of revenues in FY21 (12% in FY18) Leveraging SG&A spend down as a % of revenue Opportunistic portfolio manageme
Slide 46: Broadening Value Streams
Broadening Value Streams International and New Products account for approximately 24% of total revenues in FY23 1% 76% 5% 7% FY18 7% FY21 88% FY23 99% 17% OAS Base New Products International
Slide 47: FY21 Financial Goals
FY21 Financial Goals CSI Cost Down Material Cost Reduction Programs Volume Driven OH Leverage LEAN Productivity Initiatives Revenues Gross Margins R&D Investments Adjusted EBITDA Net Income • $300M–$350M • 78%–80% • Approximately $50M • 8%–10% • 3%–5% • CAGR = 11%-17% • Ongoing cost (14%-17% of reve
Slide 48: Poised for Significant Long-Term Revenue Growth
Poised for Significant Long-Term Revenue Growth Historical Revenue Future Revenue $435M–$500M $300M–$350M $240M–$250M $217M $205M $182M $178M $137M FY14 FY15 FY16 FY17 FY18 FY19 FY21 FY23 12% 15%–18% CAGR 5-Year CAGR
Slide 49: Appendix: Non-GAAP Financial Measures
Appendix: Non-GAAP Financial Measures To supplement CSI's consolidated condensed financial statements prepared in accordance with GAAP, CSI uses a non-GAAP financial measure referred to as "Adjusted EBITDA" in this presentation. Reconciliations of this non-GAAP measure to the most comparable U.S. GA
Slide 50: Appendix: Non-GAAP Financial Measures
Appendix: Non-GAAP Financial Measures The following is an explanation of each of the items that management excluded from Adjusted EBITDA and the reasons for excluding each of these individual items: -- Stock-based compensation. CSI excludes stock-based compensation expense from its non-GAAP financia
Slide 51: Analyst Day Meeting
Analyst Day Meeting Scott R. Ward Chairman, President & CEO July 31, 2018
Slide 52: Safe Harbor
Safe Harbor FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Report Act of 1995, which are provided under the protection of the safe harbor for forward-looking statements provided by that Act. For examples, state
Slide 53: Creating Shareholder Value
Cardiovascular Systems, Inc. Creating Shareholder Value Leveraging a A Compelling Creating Competitive Financially Strong with the Strong Core Business Growth Strategy Advantage Team and Talent to Win Improving outcomes for Driving market leading Highest quality Sustaining double digit growth comple
Slide 54: David E. Kandzari, MD
David E. Kandzari, MD Director of Interventional Cardiology and Chief Scientific Officer Piedmont Heart Institute Dr. David E. Kandzari is the Director, Interventional Cardiology of the Piedmont Heart Institute and Chief Scientific Officer for the Piedmont Healthcare in Atlanta, Georgia. Dr. Kandzar
Slide 55: Martin B. Leon, MD
Martin B. Leon, MD Director, Center for Interventional Vascular Therapy Columbia University Medical Center Martin B. Leon, MD, is a Professor of Medicine at Columbia University College of Physicians and Surgeons and Director of the Center for Interventional Vascular Therapy (CIVT) at NewYork-Presbyt
Slide 56: Jeffrey S. Points, Chief Financial Officer
Jeffrey S. Points Chief Financial Officer Cardiovascular Systems, Inc. Mr. Points joined CSI in September 2007 as Corporate Controller, became Senior Director and Controller in July 2013, Corporate Controller and Treasurer in January 2015, Vice President, Corporate Controller and Treasurer in May 20
Slide 57: Rhonda J. Robb, Chief Operating Officer
Rhonda J. Robb Chief Operating Officer Cardiovascular Systems, Inc. Ms. Robb joined CSI as Chief Operating Officer in January 2018. Ms. Robb brings more than 30 years of medical device leadership to the company. Prior to CSI, she held several positions at Medtronic, most recently as Vice President a
Slide 58: Scott R. Ward, Chairman, President & CEO
Scott R. Ward Chairman, President & Chief Executive Officer Cardiovascular Systems, Inc. Mr. Ward has been a member of the CSI Board of Directors since 2013 and has served as Chairman since November 2014. Mr. Ward served as our Interim President and Chief Executive Officer commencing in November 201
Slide 59: Trademarks
CSI®, Diamondback®, Diamondback 360®, GlideAssist®, ViperWire® and ViperWire Advance® are trademarks of Cardiovascular Systems, Inc. © 2018 Cardiovascular Systems, Inc. Sapphire® and OrbusNeich® are trademarks of OrbusNeich Medical, Inc.